NXTCNextCure, Inc.

NXTC Stock Price, Valuation & Chart | NextCure, Inc.

Compare

$7.350+0.55 (+8.09%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology NXTC intrinsic value NXTC calculated fair value vs price

Overview Financials Dividends Ratios

NXTC Historical price chart

NXTC Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization26.55M

PE Ratio-0.43

EPS-17.19

Trading Volume112.61K

Today's High/Low7.44/6.71

Dividend Yield0.00

52 Week High/Low15.74/1.55

Shares Outstanding3.61M

NXTC Financial Statement

NXTC Analyst ratings

NXTC Analysis & performance metrics

NXTC Company profile

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by…

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in…

NXTC Management team

Name

Position

Sebastien Maloveste Ph.D.

Senior Vice President of Business Development

Michael S. Richman MSBACEO

Co-Founder, Chief Executive Officer, President & Director

Timothy Mayer Ph.D.COO

Chief Operating Officer

Lieping Chen M.D., Ph.D.

Co-Founder & Chairman of Scientific Advisory Board

Steven P. Cobourn CPACFO

Chief Financial Officer

Udayan Guha M.D., Ph.D.

Chief Medical Officer

Solomon Langermann Ph.D.

Chief Scientific Officer

Kevin G. Shaw

Senior Vice President & General Counsel

Name

Position

Sebastien Maloveste Ph.D.

Senior Vice President of Business Development

Michael S. Richman MSBACEO

Co-Founder, Chief Executive Officer, President & Director

Timothy Mayer Ph.D.COO

Chief Operating Officer

Lieping Chen M.D., Ph.D.

Co-Founder & Chairman of Scientific Advisory Board

Steven P. Cobourn CPACFO

Chief Financial Officer

Udayan Guha M.D., Ph.D.

Chief Medical Officer

Solomon Langermann Ph.D.

Chief Scientific Officer

Kevin G. Shaw

Senior Vice President & General Counsel

Management Team

Sebastien Maloveste Ph.D.

Senior Vice President of Business Development

Michael S. Richman MSBACEO

Co-Founder, Chief Executive Officer, President & Director

Timothy Mayer Ph.D.COO

Chief Operating Officer

Lieping Chen M.D., Ph.D.

Co-Founder & Chairman of Scientific Advisory Board

Steven P. Cobourn CPACFO

Chief Financial Officer

Udayan Guha M.D., Ph.D.

Chief Medical Officer

Solomon Langermann Ph.D.

Chief Scientific Officer

Kevin G. Shaw

Senior Vice President & General Counsel

Management

Sebastien Maloveste Ph.D.

Senior Vice President of Business Development

Michael S. Richman MSBACEO

Co-Founder, Chief Executive Officer, President & Director

Timothy Mayer Ph.D.COO

Chief Operating Officer

Lieping Chen M.D., Ph.D.

Co-Founder & Chairman of Scientific Advisory Board

Steven P. Cobourn CPACFO

Chief Financial Officer

Udayan Guha M.D., Ph.D.

Chief Medical Officer

Solomon Langermann Ph.D.

Chief Scientific Officer

Kevin G. Shaw

Senior Vice President & General Counsel

Total 8 executives

NXTC Frequently asked questions

What is NextCure, Inc. (NXTC) Stock Price?

Current stock price of NextCure, Inc. (NXTC) stock is $7.350. The stock price is +8.09% higher in the session. The intraday range can be seen from this page. Volume of NextCure, Inc. (NXTC) stock is 112.61K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the NextCure, Inc. (NXTC) stock price going up or down today?

The stock price of NextCure, Inc. (NXTC) can change with earnings, company news, and overall market sentiment. NextCure, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the NextCure, Inc. stock expensive at its current price?

Whether NextCure, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for NXTC on this page is -0.43. EPS on this page is -17.19. Compare those figures with peers and growth expectations before deciding if the current NextCure, Inc. price is justified.

How has the stock price of NextCure, Inc. (NXTC) performed historically?

Historical performance for NextCure, Inc. (NXTC) is shown on the price chart on this page. Review multi-period moves alongside volume to see how NXTC reacted to past earnings and market events.

Should I buy NextCure, Inc. (NXTC) stock, at this price?

Buying NextCure, Inc. (NXTC) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.